Bayesian hierarchical EMAX model for doseâ  response in early phase efficacy clinical trials by Gajewski, Byron J. et al.
Received: 2 October 2018 Revised: 14 March 2019 Accepted: 14 March 2019
DOI: 10.1002/sim.8167
RE S EARCH ART I C L E
Bayesian hierarchical EMAXmodel for dose-response in
early phase efficacy clinical trials
Byron J. Gajewski1 Caitlyn Meinzer2 Scott M. Berry1,3 Gaylan L. Rockswold4
William G. Barsan5 Frederick K. Korley5 Renee’ H. Martin2
1Department of Biostatistics & Data
Science, University of Kansas Medical
Center, Kansas City, Kansas
2Department of Public Health Sciences,
Medical University of South Carolina,
Charleston, South Carolina
3Berry Consultants, LLC, Austin, Texas
4Hennepin County Medical Center,
Minneapolis, Minnesota
5Department of Emergency Medicine,
University of Michigan, Ann Arbor,
Michigan
Correspondence
Byron J. Gajewski, Department of
Biostatistics & Data Science, University of
Kansas Medical Center, Mail Stop 1026,
3901 RainbowBlvd, Kansas City, KS 66160.
Email: bgajewski@kumc.edu
Funding information
National Institute of Neurological
Disorders and Stroke of the National
Institutes of Health, Grant/Award
Number: U01NS095926
A primary goal of a phase II dose-ranging trial is to identify a correct dose before
moving forward to a phase III confirmatory trial. A correct dose is one that is
actually better than control. A popular model in phase II is an independent
model that puts no structure on the dose-response relationship. Unfortunately,
the independent model does not efficiently use information from related doses.
One very successful alternate model improves power using a pre-specified
dose-response structure. Past research indicates that EMAXmodels are broadly
successful and therefore attractive for designing dose-response trials. However,
there may be instances of slight risk of nonmonotone trends that need to be
addressed when planning a clinical trial design. We propose to add hierarchi-
cal parameters to the EMAX model. The added layer allows information about
the treatment effect in one dose to be “borrowed” when estimating the treat-
ment effect in another dose. This is referred to as the hierarchical EMAXmodel.
Our paper compares three different models (independent, EMAX, and hierar-
chical EMAX) and two different design strategies. The first design considered is
Bayesian with a fixed trial design, and it has a fixed schedule for randomization.
The second design is Bayesian but adaptive, and it uses response adaptive ran-
domization. In this article, a randomized trial of patients with severe traumatic
brain injury is provided as a motivating example.
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1 INTRODUCTION
Phase II dose-ranging studies can have multiple learning objectives. While this can be phrased as “understanding the
dose-response curve,” we typically are interested in identifying the best therapeutic dose and understanding whether
that best dose provides a therapeutic benefit worthy of conducting confirmatory phase III trials. Statistical identifica-
tion of a dose and whether it is effective enough to move forward depends on the modeling assumptions about the
dose-response relationship. As early phase trials tend to be smaller in size, dose-response modeling can improve the
strength of these decisions. In this paper, we present a strong yet flexible dose-responsemodel that can have general use in
many dose-ranging trials. We demonstrate its use in a dose-ranging trial of hyperbaric oxygen for the treatment of severe
traumatic brain injury (TBI).
An important initial step in the design of a phase II trial having quantitative doses is to identify the functional form that
will be used in the primary analysis. One of the most popular dose-response models is the pairwise independent model,
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whereby individual doses are considered independent and for analysis purposes are individually compared to each other
and to control. This pairwise independent model has no structure between doses. From the Bayesian framework when
using a flat prior, this independent model has similar properties to several Fisher's exact tests for categorical data.1 This
lack of structure between the doses can have inefficiencies when there is smoothness to the dose-response curve. This
can result in lower power for identification of the correct dose, as well as wider intervals relative to alternative model
strategies. The risk of assuming a relationship is the misspecification of the model, potentially leading to poor inferences.
Alternatively, with the addition of assumptions regarding the dose response relationship into the modeling framework
(ie, response improves with increasing dose up to some threshold), there can be improved precision in the estimation
of the efficacy at each dose, leading to better dose selection and better go/no-go decision. There are many options for
the functional form of models that one can choose for inferences, including, but not limited to, EMAX, logistic, double
logistic, exponential, normal dynamic linear, and quadratic.2 While all of these models have their particular benefits
and drawbacks depending on the true functional form, the EMAX model with “Hill” parameter close to 1.0* has been
shown to provide good empirical fit for designing and analyzing dose-response data across awide range of pharmaceutical
studies.3 The impressive empirical success of the parametric EMAXmodel makes it quite attractive for dose-ranging trials
and can provide improved power and precision when appropriate. Bretz et al2 provide an approach that is a hybrid of
a multiple comparisons (through statistical testing) and modeling techniques. This “blend” of modeling approaches is
called multiple comparison procedure or by using a modeling approach (MCPMod)4 and demonstrated strong in proof of
activity probabilities, including the EMAXmodel. Thus, parametric EMAXmodels should be considered in the design of
future dose-response studies, especially when there is strong belief in a monotonic dose-response relationship.
Unlike the situations where the EMAX model has been successful, there may be dose response examples where non-
monotonic or non-EMAX relationships may be plausible. Such examples include the situation where a higher dose may
cause decreased tolerability or practical implementation issues (eg, more intense intervention mitigates increased side
effects and decreases response) causing decreased efficacy or a plateau effect. This risk of nonmonotonic dose-response
potential motivated the need formore flexible, yet powerful, models. An alternative strategy is proposed, which includes a
single dose-responsemodel that reacts to possible nonmonotonic relationships yet preserves the efficiencies in power and
precision of the EMAXmodel. One approach that preserves functional model efficiencies but is fairly robust to nonmono-
tonicity utilizes the EMAX model with the addition of random effect parameters for each dose that represent variations
from the EMAX curve per dose. Each of the random effects per dose is modeled hierarchically. Essentially, the random
effect deviations for each dose are added to the EMAX curve. Because this off-curve effect for dose is modeled hierarchi-
cally with amean of zero,5 their estimates shrink towards zero, and the amount of shrinkage depends dynamically on how
well the EMAX model captures the overall trend in the empirical dose-response data. For example, if the EMAX model
fit the data perfectly, the random effect parameters will have strong shrinkage towards zero and the dose response-curve
will be an EMAX. However, if there is deviation from the EMAXmodel then the off-curve effects will shrink less towards
zero, creating a more flexible fit of the dose-response. Use of the hierarchical EMAX model provides a robust means to
have some of the efficiencies in power and precision of the EMAX model, while also allowing increased flexibility to the
model to address deviations if necessary.
The focus of this article is to present and discuss the hierarchical EMAX model and its use for an ongoing early phase
dose selection study. The motivating example is a randomized trial of patients with severe TBI with the goal of selecting
among seven possible active doses compared to control to achieve favorable functional outcomes. Three different models
and two different design strategies are compared. The three models compared are (1) pairwise independent, (2) EMAX,
and (3) hierarchical EMAX. Each of these models is compared across two different designs: (1) fixed randomization and
(2) response adaptive randomization (RAR). Results of a simulation study can be discussed more generally, where the
same general approach also applies to other randomized dose-ranging trials.
2 METHODS
2.1 Motivating trial
The motivating trial is the Hyperbaric Oxygen Brain Injury Treatment (HOBIT) trial (NCT02407028).6 This is a phase II
Bayesian adaptive clinical trial for selecting the optimal dose regimen of hyperbaric oxygen treatment, defined as the reg-
imen (hyperbaric oxygen at different pressure levels with or without normobaric hyperoxia), which produces the greatest
*The EMAX with Hill parameter = 1 is called “hyperbolic EMAX” model in the literature but we refer to it as “EMAX.”
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TABLE 1 Dosing each of the arms in the traumatic brain injury trial
Dose Index OTUs Dose Strength
d ArmName 𝝂d * 100 𝝂d
d = 1 Control (1.0 ATA) N/Aa N/Aa
d = 2 1.5 ATA 260 𝜈2 = 2.60
d = 3 2 ATA 417 𝜈3 = 4.17
d = 4 NBH (100% FiO2 at 1.0 ATA) 540 𝜈4 = 5.40
d = 5 2.5 ATA 592 𝜈5 = 5.92
d = 6 1.5 ATA + NBH 620 𝜈6 = 6.20
d = 7 2 ATA + NBH 776 𝜈7 = 7.76
d = 8 2.5 ATA + NBH 952 𝜈8 = 9.52
aNOTE: In the control arm, subjects will be at 1.0 ATA; however, the percent of FiO2
will not be regulated. Thus, it is theoretically possible that these subjects are accumulat-
ing oxygen toxicity units (OTUs). For the purposes of this study, they will consider the
“dose” to be zero and this arm will be modeled separately. The FiO2 will be recorded
throughout the study. Patients will receive at least 21% O2 outside of the chamber, but
the level of oxygen supplementationmay be higher though not typically exceeding 50%.
improvement in the rate of good neurological outcome versus standard of care for subjects with severe TBI. A second goal
of this phase II trial is to determine if there is any hyperbaric treatment that has at least a 50% probability of demonstrat-
ing improvement in the rate of good neurological outcome versus a control (ie, standard care) in a subsequent phase III
confirmatory trial, assumed to be 500 in the control and 500 in the arm treated with the selected optimal dose regimen of
hyperbaric oxygen.
HOBIT is designed as a multicenter, prospective, randomized, adaptive phase II clinical trial. The primary outcome
is a sliding dichotomized severity7 adjusted GOS-E at 6 months (26 weeks). The trial will explore seven different active
treatment arms for relative efficacy in comparison of the control arm. Subjectsmay be randomized to hyperbaric oxygen at
one of four possible atmospheric pressures (1.0, 1.5, 2.0, and 2.5 atmospheres absolute [ATA]) with or without additional
100% normobaric oxygen (NBH).
2.1.1 Dose
The original study design6 uses a Bayesian adaptive design with RAR, early stopping for success or futility, and longitudi-
nal modeling to handle the missing data for subjects with incomplete data at the time of an interim analysis. The primary
outcome uses a pairwise independent model (described later) as the primary analysis. Following NIH peer review sug-
gestion, it was decided to improve efficiency with a more structured dose-response model. Two possible definitions of
dose were considered—one in which the two factors of treatment—4 levels of atmospheric pressure, and added use of
NBH—were modeled separately, and secondarily where the dose was defined as a singular monotonic dose as a func-
tion of the total oxygen toxicity acquired during treatment. We chose the latter because of its strong power and precision.
Table 1 defines the eight treatment arms considered in the trial. Dose strength as defined in Table 1 is the daily oxygen
toxicity units per 100 (OTU/100). See the Appendix for specific calculations of OTU dose strength.
2.2 Models
The probability an individual subject has a favorable outcome, Pd, is modeled for each dose, where dose is indexed
d ∈ {1, … , 8}. We use 𝜈d ∈ {2.6, 4.17, 5.4, 5.92, 6.2, 7.76, 9.52} as the effective dose strength, for example, 𝜈2 = 4.17, for the
dose indexed d = 2. The probability of a favorable outcome across doses is modeled with three different dose-response
models for all inferences in the trial. Assume all of the nd subjects randomized to dose index d have a summed binomial
outcome Yd
Yd ∼ Binomial(nd,Pd).
The log-odds of the probability of favorable outcomes, 𝜃d = log
(
Pd
1−Pd
)
, are modeled. In addition, for all models the single
control arm (indexed d = 1) is modeled separately from the active doses and has a prior distribution of 𝜃1∼N(−.41, .752).
This vague prior on the P1 scale has a median of 0.40 and 95% equal-tailed interval of .09-.83.
In the following sections, the three different dose-response models for the active doses are described.
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2.2.1 Independent model
The pairwise independent model has no structure in the active dose portion of the model. Specifically, we model the
active doses with independent prior distributions
𝜃d ∼ N(−0.41,12). d ∈ {2, … , 8} .
2.2.2 EMAXmodel
The specification of the EMAXmodel is
𝜃d = 𝜙1 +
𝜙2𝜈d
𝜈d + 𝜙3
, d ∈ {2, … , 8} ,
where 𝜈d is the effective dose strength. The EMAX parameters are 𝜙1, 𝜙2, and 𝜙3.
• 𝜙1 is a constant offset, and the logistic response when the effective dose strength is 0. The prior distribution is 𝜙1 ∼ N
(−0.41,12).
• 𝜙2 is a scalar coefficient of the fraction of the response due to the effective dose strength. It is the theoretical maximum
effect above the constant offset that can be achieved. The prior distribution is 𝜙2 ∼ N(0,52).
• 𝜙3 is a positive scalar representing the effective dose strength that achieves 50% of the theoretical maximal effect. The
prior distribution is 𝜙3 ∼ N+(3,102). The notation N+ represents a positively truncated normal distribution.
As dose tends to infinity, the theoretical maximum efficacy on the logit scale is lim𝜈d→∞(𝜙1 +
𝜙2𝜈d
𝜈d+𝜙3
) = 𝜙1 + 𝜙2,; thus, it is
called the EMAX. For an effective dose-strength of 𝜈d = 𝜙3, the log-odds is 𝜙1 + 𝜙22 .
2.2.3 Hierarchical EMAXmodel
TheHierarchical EMAXmodel builds on the EMAX using the following structure:
𝜃d = 𝜙1 +
𝜙2𝜈d
𝜈d + 𝜙3
+ 𝜓d, d ∈ {2, … , 8} ,
where νd is the effective dose strength and the individual dose effects are modeled as
𝜓d ∼ N
(
0, 𝜙24
)
, d ∈ {2, … , 8}.
The hyperparameters are constrained such that∑𝜓d = 0. The prior distribution is 𝜓d ∼ N(0, 𝜙24), where the hyperprior
𝜙24 ∼ Inverse-Gamma(0.1, 0.001). All other priors are the same as defined in the EMAX model.
Themodel has amean curve that is the EMAXmodel, but with an additional additive term per dose,𝜓d, for an off-curve
effect that allows for a more flexible model. The additive 𝜓d terms are considered hierarchical because a priori they share
a common normal distribution having a hyperprior. The beauty of the random effect modeling is that, when the EMAX
provides a good fit to the data, the random effect parameters, 𝜓d, are shrunk toward 0, hence gaining the power of the
EMAX structure. When there are significant deviations from the EMAX model, the hyperparameter 𝜙24 will be larger
and there is less shrinkage towards the EMAX model, allowing the individual dose effects to create a custom fit. At the
extremes, 𝜙24 = 0 the model is the EMAX model, and when 𝜙
2
4 → ∞, the model is the pairwise independent model. The
hierarchical EMAXmodel will be like the EMAXmodel, unless the data deviates from the EMAX relationship, then it will
respond accordingly. This feature suggests that its power lies between the independent and EMAX models but is more
robust to model misspecifications.
It is worth a bit more discussion as to how the prior distribution for the hyperprior 𝜙24 ∼ Inverse-Gamma(0.1, 0.001)
was derived. One rational is to specify 𝜙24 ∼ Inverse-Gamma
(
Λn
2 ,
Λ2
𝜇
Λn
2
)
, where Λμ is the hierarchical prior central value
and Λn is the hierarchical prior weight. One must select these parameters carefully to avoid overfitting or underfitting of
themodel.8 A very sound strategy is to specifyΛμ as a reasonable value of the upper limit in the difference in responses on
the logit scale. In our application to the HOBIT trial design, we found Λμ = .1 to be reasonable. For the prior weight, we
find that, in general, Λn = 1 is a very good start; however, after some tweaking through simulations, we ultimately went
with Λn = .2. The choices for the specification of these parameters will depend on outcome type and expectation of the
dose-response for the particular application.
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2.3 Bayesian quantities of interest
In order to draw conclusions from the abovemodel, the posterior probability for each of the doses is converted to quantities
of interest related to the main questions: the probability that each dose is the maximal effective dose, the probability each
dose is superior to the control, and the predictive probability a dose would win a phase III trial compared to control. The
Bayesian quantities rely on calculating the joint posterior distribution of the probability of a favorable outcome for each
dose. These joint posteriors are calculated using standardMarkov chainMonte Carlo (MCMC) algorithms. The quantities
of interest are as follows.
2.3.1 Posterior probability of treatment difference
For each active dose, d= 2,… ,8, the posterior probability that the dose is superior to control, P(Pd − P1 > 0), is calculated.
The estimate of this quantity is the proportion of MCMC samples in which Pd > P1.
2.3.2 Maximum effective dose
The maximum effective dose (DMax) is the dose with the greatest probability of a favorable outcome. The posterior proba-
bility each dose is the maximally effective dose, Pr(DMax), is calculated as the frequency of the MCMC samples in which
each dose is the maximum.
2.3.3 Posterior predictive probability of future trial success
We assume a future phase III trial would be a fixed design, equally randomized 1000 subjects between control and one
active dose, with a final analysis a test of superiority. Thereby, for each active dose, the predictive probability of success in
a future hypothetical trial is calculated as Pr(Phase III Success; n = 500, 𝛼 = 0.025, 𝛿 = 0). For each dose, this is calculated
by averaging the power function over the posterior distribution for each dose and the control probabilities of favorable
outcomes. This is different from the power for such a trial, in that the power calculations typically assume a fixed treatment
effect, whereas the predictive probability of success averages over the posterior distribution of the treatment effect. Thus,
knowledge of the treatment effect and the uncertainty in that knowledge are formally incorporated.
2.4 Final evaluation criteria
At the final analysis, the trial is considered successful if all of the following criteria are satisfied:
Pr(Pd > P1) > 𝛽 for d = greatest Pr(D𝑀𝑎𝑥), and
Pr(Phase III Success;n = 500, 𝛼 = 0.025, 𝛿 = 0) > 0.5 for d = greatest Pr(D𝑀𝑎𝑥).
Note, for fixed 𝛽, the type I error rate changes depending on the model choice for the final analysis. Thus, so that all
models have the same type I error rate 𝛽 will vary by the choice of model used. To provide 10% type I error rates across
models, 𝛽 is set to 0.975, 0.92, and 0.922 for independent, EMAX, and hierarchical EMAX models, respectively.
3 RESULTS
3.1 Illustrative examples
In this section, three single simulated trials are used as examples to illustrate the differences between independent, EMAX,
and hierarchical EMAX models. These example datasets were created for illustrative purposes and then fitted using the
Windows Bayesian inference Using Gibbs Sampling (WinBUGS)9 code in the Supporting Information. In these examples,
the total sample size is 200 with 39 allocated to control and the rest equally allocated to the seven active doses.
Figure 1 and Table 2 depict the three single simulated datasets whereby it is assumed that there is a large monotonic
dose effect, an effect for the NBH dose only, and an overdose effect. The large monotonic effect is a scenario in which
favorable response increases with dose in the active arms in a largemonotone fashion. The second example is a scenario
in which higher responses in the active doses take place in a monotonic fashion but only in those doses that involveNBH.
The third example is a scenario in which toxicity is involved and results in an upside down U-shape distribution. Here,
toxicity prevails in doses with higher oxygen toxicity units and thus causes a high number of poor responses at higher
doses.
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FIGURE 1 Illustrative data for the exploration of posterior distributions for assumed responses [Colour figure can be viewed at
wileyonlinelibrary.com]
TABLE 2 Illustrative data for the exploration of posterior distributions for assumed responses
Dose d = 1 d = 2 d = 3 d = 4 d = 5 d = 6 d = 7 d = 8
Strength Control 2.60 4.17 5.40 5.92 6.20 7.76 9.52
n 39 23 23 23 23 23 23 23
Large Monotone
Response y 16 8 10 11 12 14 16 18
%Response 100*y/n 41.0% 34.8% 43.5% 47.8% 52.2% 60.9% 69.6% 78.3%
NBH Only
Response y 16 8 8 18 8 18 18 18
%Response 100*y/n 41.0% 34.8% 34.8% 78.3% 34.8% 78.3% 78.3% 78.3%
Overdose
Response y 16 8 10 12 18 12 4 2
%Response 100*y/n 41.0% 34.8% 43.5% 52.2% 78.3% 52.2% 17.4% 8.7%
3.1.1 Example 1: large monotone effect
Figure 2 provides the median of the posterior distribution and 95% credible intervals with the observed rates for the
three models. For a non-Bayesian, this is analogous to a point estimate and 95% confidence interval. The independent
model has wider credible intervals than the EMAX and the hierarchical EMAX models. The latter two models are very
similar in location and width, demonstrating better precision than the independent model. The monotonic increase of
the response and intervals, as well as the observed rates, is covered by all models. The reason that the latter two models
appear so similar to one another is because the EMAX portion in both models follows the monotone pattern and the
off-curve effect at each dose is essentially zero as illustrated by its posteriormedian.With respect to the Bayesian quantities
of interest across dose as shown in Table 3, the posterior probability of treatment difference and posterior predictive
probability of future trial success are all very similar across EMAX and hierarchical EMAX and doses, but different for the
independent model as it spreads P(DMax) across the three highest doses. For all three models, d = greatest Pr(DMax) = 8,
which has an effective dose strength of 𝜈8 = 9.52, and at that dose, all of the models have Bayesian quantities that lead to
trial success, specifically Pr(Pd > P1) > 0.975, 0.92, and 0.922 for independent, EMAX, and hierarchical EMAX models,
respectively, and Pr(Phase III Success; n= 500, 𝛼 = 0.025, 𝛿 = 0)> 0.5 for d= 8. In summary for the largemonotonic effect,
the EMAX and hierarchical EMAX models provide similar conclusions and both are preferable over the independent
model.
3.1.2 Example 2: NBH effect
As with the previous example, Figure 3 illustrates the median of the posterior distribution and 95% credible intervals
with the observed rates for the independent, EMAX, and hierarchical EMAXmodels. In this case, the independent model
covers all of the point estimates but has wide intervals. The nonlinear response is not well represented by the EMAX
model. It underestimates two of the early doses that use NBH and overestimates some of the other doses that do not have
NBH. However, the added flexibility of the hierarchical EMAX model follows the patterns quite well, covering all of the
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FIGURE 2 Results for fitting models in the large effect example. The “◻” in the first three frames represent the observed rate and the
shaded regions are the 2.5%-tile and 97.5%-tile from models (eg, 95% intervals) for Pd for all models. The last frame shows the 50%-tile (point
estimate) and 2.5%-tile and 97.5%-tile for 𝜓d in the hierarchical EMAX model [Colour figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Bayesian quantity results from fitting the large monotonic effect example
Large Effect d = 1 d = 2 d = 3 d = 4 d = 5 d = 6 d = 7 d = 8
Control 2.60 4.17 5.40 5.92 6.20 7.76 9.52
P(DMax) Independent 0.00 0.00 0.00 0.01 0.02 0.07 0.24 0.66
EMAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
Hierarchical EMAX 0.00 0.00 0.00 0.00 0.01 0.01 0.08 0.89
Pr(Pd > P1) Independent 0.00 0.32 0.57 0.69 0.79 0.92 0.98 1.00
EMAX 0.00 0.43 0.81 0.95 0.98 0.98 1.00 1.00
Hierarchical EMAX 0.00 0.43 0.79 0.93 0.96 0.98 0.99 1.00
Pr(Phase III Success) Independent 0.02 0.17 0.37 0.49 0.61 0.81 0.93 0.98
EMAX 0.03 0.22 0.57 0.82 0.88 0.90 0.97 0.99
Hierarchical EMAX 0.03 0.23 0.55 0.78 0.85 0.89 0.97 0.99
observed rates. As shown in the fourth panel of Figure 3, the hierarchical model has better coverage because the off-curve
effect is larger than zero at each if the four NBH doses. The Bayesian quantities of interest across doses shown in Tables 4
also provide information about the utility of these three models. The maximum effective dose is essentially zero for all
the doses except the highest for the EMAX, whereas the hierarchical EMAXmodel spreads the probability across more of
the doses with NBH. In addition, the posterior probability of future trial success has a notable divergence in agreement
at dose 5.92 across the two parametric models. However, when going to three digits, just like in the previous example,
all three models d = greatest Pr(DMax) = 8, which has an effective dose strength of 𝜈8 = 9.52, and at that dose, all of the
models have Bayesian quantities that lead to trial success, specifically Pr(Pd > P1)> 0.975, 0.92, and 0.922 for independent,
EMAX, and hierarchical EMAXmodels, respectively, and Pr(Phase III Success; n = 500, 𝛼 = 0.025, 𝛿 = 0) > 0.5 for d = 8.
In this situation, the hierarchical EMAX model provides more flexibility and thus investigators would have increased
insight into the best dose to carry forward into the future trial.
3.1.3 Example 3: overdose
Figure 4 provides the median of the posterior distribution and 95% credible intervals with the observed rates for the inde-
pendent, EMAX, and hierarchical EMAX models for the overdose example. Again, the independent covers the observed
rates but with wide intervals. Further, the nonlinear response is not well modeled at all by the EMAX model. It severely
under estimates one of the middle doses before the dose becomes harmful. However, as in the NBH example, the flexibil-
ity of the hierarchical EMAXmodel follows the patterns quite well, covering all of the observed rates. The reason that the
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FIGURE 3 Results for fitting models in theNBH only effect example. The “◻” in the first three frames represent the observed rate and
the shaded regions are the 2.5%-tile and 97.5%-tile from models (eg, 95% intervals) for Pd for all models. The last frame shows the 50%-tile
(point estimate) and 2.5%-tile and 97.5%-tile for 𝜓d in the hierarchical EMAX model [Colour figure can be viewed at wileyonlinelibrary.com]
TABLE 4 Bayesian quantity results from fitting theNBH only example
NBH Only d = 1 d = 2 d = 3 d = 4 d = 5 d = 6 d = 7 d = 8
Control 2.60 4.17 5.40 5.92 6.20 7.76 9.52
P(DMax) Independent 0.00 0.00 0.00 0.25 0.00 0.25 0.25 0.25
EMAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
Hierarchical EMAX 0.00 0.00 0.00 0.16 0.00 0.18 0.25 0.40
Pr(Pd > P1) Independent 0.00 0.32 0.32 1.00 0.32 1.00 1.00 1.00
EMAX 0.00 0.49 0.90 0.99 0.99 1.00 1.00 1.00
Hierarchical EMAX 0.00 0.43 0.54 1.00 0.61 1.00 1.00 1.00
Pr(Phase III Success) Independent 0.02 0.18 0.17 0.98 0.17 0.98 0.98 0.98
EMAX 0.03 0.27 0.71 0.92 0.96 0.97 0.99 1.00
Hierarchical EMAX 0.03 0.24 0.35 0.98 0.44 0.99 0.99 0.99
hierarchical EMAXmodel does a better job of coverage is because, as shown in the fourth panel of Figure 4, the off-curve
effect is bumped up at the middle dose and then goes down during the more harmful later doses. Table 5 presents the
Bayesian quantities of interest across doses. In this scenario, the maximum effective dose is too small for detection by the
EMAXmodel, whereas the hierarchical EMAXmodel correctly identifies themiddle dose as the best. In addition, the pos-
terior probabilities correctly reflect what is expected given this scenario of toxicity. The hierarchical EMAXmodel choses
the middle dose as having over twice the probability of being better than control relative to the EMAX model. Lastly, the
probability of future trial success has a notable difference in this dose across the two models. Turning to the independent
model, in terms of the results in Figure 4 and Table 5, it has very similar results to the hierarchical EMAX, suggesting
that both may behave similarly in this overdose effect shape. In this example, the three models resulted in different trial
conclusions. For both the independent as well as the hierarchical EMAX models, d = greatest Pr(DMax) = 5, which has
an effective dose strength of 𝜈5 = 5.92. The EMAX model has a lower dose with d = greatest Pr(DMax) = 2, which has
an effective dose strength of 𝜈2 = 2.60. However, only the independent and the hierarchical EMAX achieve trial success
because Pr(Pd > P1) > 0.975 and 0.922, respectively, and Pr(Phase III Success; n = 500, 𝛼 = 0.025, 𝛿 = 0) > 0.5 for d = 5.
The EMAX does not achieve trial success as both Pr(Pd > P1) < 0.92 and Pr(Phase III Success; n = 500, 𝛼 = 0.025, 𝛿 = 0)
< 0.5 for d = 2. We will further explore this result in the next section using several simulated datasets. In the situation of
toxicity, the hierarchical EMAX model would provide investigators with a clear dose winner that reflects the nonlinear
trend in the observed rates.
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FIGURE 4 Results for fitting models in the overdose effect example. The “◻” in the first three frames represent the observed rate and the
shaded regions are the 2.5%-tile and 97.5%-tile from models (eg, 95% intervals) for Pd for all models. The last frame shows the 50%-tile (point
estimate) and 2.5%-tile and 97.5%-tile for 𝜓d in the hierarchical EMAX model [Colour figure can be viewed at wileyonlinelibrary.com]
TABLE 5 Bayesian quantity results from fitting the overdose example
Overdose d = 1 d = 2 d = 3 d = 4 d = 5 d = 6 d = 7 d = 8
Control 2.60 4.17 5.40 5.92 6.20 7.76 9.52
P(DMax) Independent 0.00 0.00 0.01 0.04 0.92 0.04 0.00 0.00
EMAX 0.00 0.93 0.00 0.00 0.00 0.00 0.00 0.07
Hierarchical EMAX 0.00 0.00 0.01 0.04 0.91 0.04 0.00 0.00
Pr(Pd > P1) Independent 0.00 0.32 0.57 0.79 1.00 0.79 0.04 0.01
EMAX 0.00 0.79 0.65 0.52 0.46 0.43 0.31 0.23
Hierarchical EMAX 0.00 0.34 0.57 0.77 0.99 0.77 0.04 0.01
Pr(Phase III Success) Independent 0.03 0.17 0.37 0.61 0.98 0.61 0.01 0.00
EMAX 0.03 0.58 0.38 0.25 0.21 0.20 0.13 0.09
Hierarchical EMAX 0.03 0.19 0.37 0.59 0.97 0.59 0.01 0.00
3.2 Simulation study
The previous section provided an illustration of the properties of the three different models using a single simulated
dataset. A more thorough investigation of the relative properties of these models (independent, EMAX, and hierarchical
EMAX), and the trial operating characteristics such as fitted response, proportion dose was identified as having the largest
P(DMax), average sample size, and proportion of timewe select the correct dose (eg, power) are evaluated through repeated
simulations using different assumptions of the dose-response curves (“large monotone,” “NBH only,” and “overdose”).
The trial operating characteristics were calculated using commercial software Fixed and Adaptive Clinical Trial Simu-
lator 6.2 (FACTS) (Berry Consultants, Austin, TX). In each scenario, 10 000 simulated trials are used. We considered two
designs both having n = 200.
First, a fixed allocation ratio of 1:4 control to active doses, spread evenly across active doses. As reported in the examples,
to provide 10% type I error rates across models, 𝛽 is set to 0.975, 0.92, and 0.922 for independent, EMAX, and hierarchical
EMAX models, respectively.
Second, a RAR allocation8 is used with the same allocation ratio of 1:4 control to active dose, but after the first 53
randomized, the allocation among active doses changes. Instead of being spread evenly across active doses, the allocation
among active doses was proportional to √
Var(𝜃d)Pr(d = DMax)
(nd + 1)
.
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TABLE 6 Favorable response rates assumptions used for simulations. Shaded
regions are doses expected to be better than control (eg, correct arm)
d = 1 d = 2 d = 3 d = 4 d = 5 d = 6 d = 7 d = 8
Effect Control 2.60 4.17 5.40 5.92 6.20 7.76 9.52
Large 0.40 0.59 0.60 0.61 0.62 0.63 0.64 0.65
NBH 0.40 0.40 0.40 0.70 0.40 0.70 0.70 0.70
Overdose 0.40 0.40 0.50 0.55 0.70 0.40 0.35 0.30
This RAR is updated after every 21 subjects are enrolled. For the RAR design, to provide 10% type I error rates across
models, 𝛽 was slightly modified to 0.970, 0.925, and 0.925 for independent, EMAX, and hierarchical EMAX models,
respectively.
The true response rates assumed for each scenario are shown in Table 6. In choosing effect sizes to evaluate the models,
the “large” response (Table 6) is expected to favor the EMAX since it is monotone; however, for “NBH” and “overdose,”
there is a nonlinear effect caused by NBH or an overdose of oxygen. Thus, these dose response effects are expected to favor
the hierarchical EMAX or independent models.
3.2.1 Fitted response and P(DMax) selection across simulations
In order to evaluate how well each model fits the proposed dose response effect, Figures 5, 6, and 7 show the estimated
means with 2.5% and 97.5% quantities for the probabilities of response and the proportion of simulations a dose was iden-
tified as having the largest P(DMax) for the fixed design (there are similar plots for the adaptive design but for brevity not
shown). These are presented so that we can understand how well the models fit the data and how these models result in
a dose as being selected as maximum response relative to control and a candidate to move forward to phase III. Recall
the dose with maximum response relative to control has to also achieve the success criteria presented in Section 2.4. Pre-
viously, it was shown that the amount of deviation from a monotone model in the Bayesian hierarchical EMAXmodel is
determined by the data, ie, the greater the deviation, the greater the spread in the drift parameters. Thus, the hierarchical
EMAX model more readily responds to deviations than the EMAX. The large effect scenario (Figure 5) shows similar-
ities between the hierarchical EMAX and EMAX. The point estimates and the 95% quantiles are almost identical. The
independent model has similar point estimates but the 95% quantiles are much wider. In addition, compared to the inde-
pendent model, the EMAX and hierarchical EMAX models have a higher frequency of correctly identifying the highest
dose as having the having the largest P(DMax).
The NBH only scenario (Figure 6) shows deviations between the hierarchical EMAX model and the EMAX model in
that the hierarchical EMAX reacts to the nonlinear spikes in the responses as the point estimates and quantiles cover
the true response probabilities whereas the EMAX model misses four doses. Like the hierarchical EMAX model, the
independent model has close point estimates and intervals that cover the truth for all doses but the intervals are wider
than the hierarchical model. However, as identified by the P(DMax), the independent model has a slightly higher chance
of selecting NBH than the hierarchical EMAX, conversely hierarchical EMAX leans more towards the highest dose than
the independent model does.
The overdose scenario (Figure 7) also shows deviations between the hierarchical EMAX model and the EMAX model
in that the hierarchical reacts to the nonlinear spikes in the responses as the point estimates and quantiles cover the true
response probabilities whereas the EMAX model severely misses two doses. The point estimates and interval widths are
similar in this scenario between hierarchical EMAX and independent models. In fact, it looks like the independent model
does pretty well in this case. The hierarchical EMAX does much better at quantifying the maximum probability at the
middle highest response rate than the EMAX. The independent model does the best in choosing the best dose.
3.2.2 Probability a correct or incorrect arm is selected: fixed trial
In evaluating the doses, the interest is the probability of selecting a treatment dose that actually is better than control (eg, a
correct arm). For these simulations, the “correct” dose, defined as concluding efficacy where Pd > P1, is dependent on the
effect assumed and is shown in Table 6 as a shaded region. The proportion of correct decisions, as well as the probability
of selecting an incorrect arm, for each model across the scenarios are provided in Table 7. The EMAXmodel is close to or
has the highest probability of choosing a correct dose, in all scenarios, except for the “overdose,” where it is fails miserably
having 0 correct decisions. But, it also has unacceptable probability of incorrect doses. The hierarchical EMAX has a
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Independent
EMAX
hierarchical EMAX 
FIGURE 5 Large monotone effect [Colour figure can be viewed at wileyonlinelibrary.com]
much higher probability of selecting a correct dose than the independent model in all scenarios except overdose case. The
independent model is the only one that performs reasonably well in the overdose scenario. Although the probability of
choosing the correct dose in the other scenarios is not as high as the other models, it does still perform very well.
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Independent 
EMAX
hierarchical EMAX
FIGURE 6 NBH only [Colour figure can be viewed at wileyonlinelibrary.com]
3.2.3 Probability a correct or incorrect arm is selected: RAR trial
Table 8 also shows the probability of choosing a correct arm and the probability of choosing an incorrect arm for each
model across the scenarios. The EMAX model has the highest probability of choosing a correct arm in the first two sce-
narios, but as with the fixed design, it does not provide acceptable probabilities for correct selection for the overdose
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Independent  
EMAX
hierarchical EMAX 
FIGURE 7 Overdose [Colour figure can be viewed at wileyonlinelibrary.com]
scenario. The hierarchical EMAX is more likely to pick a correct arm than the independent model in all scenarios except
overdose case. The hierarchical EMAXmodel has a lower probability of choosing an incorrect dose than the EMAX does.
3136 GAJEWSKI ET AL.
TABLE 7 Operating characteristics of the models for fixed design (n = 200). All designs are calibrated to have a type I
error rate of 10%
Fixed Independent EMAX Hierarchical EMAX
Effect P(Correct) P(Incorrect) P(Correct) P(Incorrect) P(Correct) P(Incorrect)
Large 0.808 0.000 0.939 0.000 0.936 0.000
NBH Only 0.899 0.003 0.950 0.012 0.960 0.004
Overdose 0.635 0.008 0.000 0.317 0.450 0.091
TABLE 8 Operating characteristics of the models for adaptive design with longitudinal modeling (nmax = 200). All
designs are calibrated to have a type I error rate of 10
Adaptive Independent EMAX Hierarchical EMAX
Effect P(Correct) P(Incorrect) P(Correct) P(Incorrect) P(Correct) P(Incorrect)
Large 0.847 0.000 0.944 0.000 0.933 0.000
NBH Only 0.945 0.001 0.979 0.002 0.972 0.004
Overdose 0.769 0.004 0.000 0.087 0.554 0.064
The independent model, while slightly worse for the large and NBH only dose response effects, offers significantly greater
protection in the case where the overdose scenario is the true treatment effect.
4 DISCUSSION
The HOBIT trial, as in many dose response phase II trials, has a clinical goal for identifying the treatment dose that
produces best outcomes for sick patients, in this case, severe TBI. It is strongly believed that higher doses of oxygen will
improve outcomes in amonotonically increasing fashion. However, these high doses have not been explicitly tested in the
clinical setting, so it is important for statisticians and clinicians to think about howmodels will react to possible deviations
from monotonicity. That is why we investigated the up and down scenarios provided by the NBH and the overdose. It
allowed us to see if our model choice is robust to risky deviations in dose response structures. Not surprisingly there was
not a clear winner across the scenarios. In thinking about the results, on the one hand obtaining a good fit across all
parameters puts us in a better place if we do not want to select the highest dose, power is important but maybe not if
the models differ by a few percentages, and the same with sample size—there is a trade-off between risk to the patient,
duration/cost of trial, but theremayneed to be additional information for estimating safety and for secondary data analysis
plans.
Because of the strong opinion of monotone structure, in this case (and many) of dose-response phase II trials, a very
good starting point is to use the EMAX approach. However, deciding whether to add the hierarchical and how to borrow
across groups depends on how much you think the true dose-response curve is likely to deviate from the EMAX. For
example, is there a strong or weak possibility of an overdose or othermechanisms that may cause nonmonotone patterns?
If there is no possibility of nonmonotone patterns, one should go with the EMAX. It is the clear winner. If there is a weak
possibility of nonmonotone patterns, one should go with the hierarchical EMAX. In this case, the amount of shrinkage
or lack of reaction to irregularities is determined by an inverse gamma hyperprior on the variance term for the off-curve
effect. The parameters in this model can be decided based on careful scenario construction and simulation can be used to
investigate the balance between power and robustness. Finally, if there are strong possibilities of nonmonotone patterns,
one should gowith the independentmodel. These decisions can bemade by investigating scenarios and simulation results
can be reviewed and discussed among investigators, DSMB, and other stakeholders such as the sponsor. These groups
should investigate power, probability of getting the correct (or incorrect) dose and the best dose, the sample size, and the
time in which it takes to finish the trial. A possible way to discuss this is by presenting plots such as the one in Figure 8
that shows the trade-off of identifying correct or incorrect doses as a function of possibility of nonmonotone patterns.
Some non-Bayesians may have more experience or comfort with traditional model averaging techniques10 than fitting
Bayesianmodels. The strategy in this paper essentially combinesmodels in themodeling stage.Model averaging combines
models in the outcomes stage.We prefer themodeling strategy described in this paper. But, for a trialist or statisticianwho
may be more comfortable in the model averaging literature, one may follow the techniques described in the frequentist
literature to combine independent doses model with EMAX to achieve a similar goal.
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FIGURE 8 Presented is the probability of identifying correct dose minus the probability of identifying incorrect dose as a function of
possibility of a nonmonotone scenario. The possibility of nonmonotone pattern produces a combination of the effects large, NBH only, and
overdose. Let 𝜋 be the probability of a nonmonotone pattern (this probability is split between the two nonmonotone patterns NBH only and
overdose), then the difference in probability correct (Pc) and probability of incorrect (PI), where I = Pc−PI, for each model is calculated as a
function of the probability of the effects; therefore, this operating characteristic becomes 𝜋ILarge + (𝜋/2)INBH + (𝜋/2)IOverdose. Notice that no
model is best across all possibilities of nonmonotone patterns; however, hierarchical EMAX model works very well across a broad range
The mention of model averaging motivates thoughts of possible future extensions to the Hierarchical EMAX model.
For example, it might be a benefit to allow a correlation between consecutive doses “residuals,” the 𝜓d's. Further, seven
doses are a lot, though more sponsors may want to consider a broad dose range with many doses (for example, in phase
II oncology therapeutic trials and other cancer related studies, such as smoking cessation and/or weight loss studies),
especially when using modeling rather than an independent doses model. The questions then become as follows: (1)
Does this work as well with fewer doses? At what point does the EMAX assumption comes to dominate? Or does added
flexibility of the hierarchical component contributes differently with more vs less doses? Tackling these issues are our
next steps in this line of research.
In conclusion, with the ability to have adequate power and other trial operating characteristics, the hierarchical EMAX
model is an important alternative in the phase II dose-response setting. Further, as a general pre-trial or trial start-up
activity in the case of phase II dose selection trials, we have found that, often, insufficient attention is devoted to the
potential vulnerabilities of the trial with respect to modeling choice. This article provides a general framework for how
other studies may approach evaluating alternative modeling choices to further safeguard the trial without appreciable
loss of power or significant modification of the underlying protocol.
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APPENDIX
DOSE CALCULATIONS
The oxygen toxicity exposure per dive is calculated as the number of minutes breathing 100% oxygen. For each dive,
subjects are compressed/decompressed at a rate of 2 feet per minute, where a 10-m dive reduces the atmospheres by
approximately 1 unit. That is, the compression or decompression time for a 1.5-ATA dive is 8.25 minutes, respectively,
16.5 minutes for a 2.0-ATA dive, and 25 minutes for a 2.5-ATA dive. That is
PO2 = 100%O2 × 𝐴𝑇𝐴 (A1)
Compression[min] =
(
PO2𝑓 − PO2s
)
× 10 m1 𝐴𝑇𝐴 ×
3.281𝑓
1 m ×
1 min
2𝑓 . (A2)
To calculate the OTU for the decompression/compression,
𝑂𝑇𝑈 =
3
11 time(mins)
PO2𝑓 − PO2i
×
⎡⎢⎢⎣
(PO2𝑓 − 0.5
0.5
) 11
6
−
(PO2i − 0.5
0.5
) 11
6 ⎤⎥⎥⎦ . (A3)
Once compressed, subjects will be treated at the specified pressure for 60 minutes, with NBH treatment defined as 100%
O2 for 3 hours following decompression. The NBHwithout HBO2 treatment will be 100% O2 for 4.5 hours at 1.0 ATA. To
calculate the OTU at constant depth,
𝑂𝑇𝑈 = time(mins) ×
(
0.5
PO2 − 0.5
) −5
6
. (A4)
Thus, the total OTU dose per dive is shown in the Table.
Compress/ OTUs Constant OTUsb NBH OTUsb Total
Dose ATA Decompress (× 2)a Pressure Time OTU per
Time Time dive
1.5 ATA 1.5 8.25 11.5 60 106.9 0 0 130.0
2 ATA 2 16.5 29.2 60 149.9 0 0 208.3
NBH (100% FiO2 at 1.0 ATA) 1 0 0.0 0 0.0 270 270 270.0
2.5 ATA 2.5 25 53.2 60 190.5 0 0 296.8c
1.5 ATA + NBH 1.5 8.25 11.5 60 106.9 180 180 310.0
2 ATA + NBH 2 16.5 29.2 60 149.9 180 180 388.3c
2.5 ATA + NBH 2.5 25 53.2 60 190.5 180 180 476.8c
aUsing the decompression/compression formula.
bUsing the constant depth formula.
cDue to differences in rounding, the effective OTU dose for arms 2.5 ATA, 2 ATA +NBH, and 2. ATA +NBH are calculated as 52, 776, and 952
(see Table 2).
